

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Shock/trauma; mucositis; asthma; rheumatoid arthritis (RA); osteoarthritis; pain	Nitric oxide synthase 2 (inducible) (NOS2; iNOS)	<i>In vitro</i> and <i>in silico</i> studies identified a NOS inhibitor that could help treat inflammation. In a whole cell assay, <i>N</i> -benzylacetamidine selectively inhibited iNOS. Ongoing work is using computer-aided design to synthesize potent and selective acetamide inhibitors of iNOS. 274150, an iNOS inhibitor from GlaxoSmithKline plc, is in Phase II testing to treat RA. KD7040, an iNOS inhibitor from Kalypsys Inc., is in Phase IIa testing to treat inflammatory neuropathic pain and post-herpetic neuralgia.	Unpatented; unlicensed	Maccallini, C. <i>et al. J. Med. Chem.</i> ; published online Feb. 9, 2009; doi:10.1021/jm800846u Contact: Rosa Amoroso, G. d'Annunzio University, Chieti, Italy e-mail: ramoroso@unich.it
		SciBX 2(8); doi:10.1038/scibx.2009.325 Published online Feb. 26, 2009		